ReviewFrontiers in aging neuroscience2026

GLP-1 receptor agonists as potential disease-modifying agents in Parkinson's and Alzheimer's disease: mechanisms, clinical trial evidence, and the neuroprotection horizon.

Mohamed Alsharif et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.